This study evaluated the cost-effectiveness of GLP-1 receptor agonists (GLP-1RAs), specifically semaglutide, for guideline-indicated patients with type 2 diabetes, modeling how the anticipated availability of generic semaglutide would change the economic value of this drug class in Canada.
Generic semaglutide availability is projected to substantially improve the cost-effectiveness of GLP-1RAs for guideline-indicated patients with type 2 diabetes, though specific incremental cost-effectiveness ratio (ICER) values were not extractable from the provided metadata.
Full paper text was not available for review — findings are inferred from the title and journal metadata only; specific numerical results, model assumptions, and study limitations cannot be confirmed.
Clinicians and health systems in Canada should anticipate that generic semaglutide entry could make GLP-1RA therapy cost-effective for a broader population of guideline-indicated type 2 diabetes patients. This may support formulary and prescribing policy updates as generics become available.
Explore related topics
